8-K: Amphastar Expands BAQSIMI Distribution in Greater China

Amphastar Pharmaceuticals has entered a 10-year exclusive distribution agreement with Nanjing Chengong Pharmaceutical to market BAQSIMI in Greater China.

Summary

• Amphastar Pharmaceuticals, Inc. (Amphastar) and Nanjing Chengong Pharmaceutical Co., Limited (Chengong) signed a Distribution Agreement on October 21, 2025.
• The agreement appoints Chengong as the exclusive distributor for Amphastar's nasal powder product, BAQSIMI, in Mainland China, Taiwan, Hong Kong, and Macau (Greater China region).
• Chengong is responsible for obtaining all necessary regulatory approvals and conducting post-marketing clinical trials in the region.
• The agreement includes minimum purchase amounts for Chengong per contract year and a profit-sharing mechanism for earnings above a specified floor price per unit.
• The term of the agreement is ten years, with an option to negotiate an extension six months prior to expiration.
• Both parties have termination rights without cause after the fourth contract year.
• The total revenue for Amphastar over the ten-year period is not determinable at this time due to variable per-unit net revenues.
• The agreement constitutes a related party transaction, as Amphastar's CEO, President, and Director, Dr. Jack Zhang, and Chairman, COO, and Director, Dr. Mary Luo, along with family members, beneficially own a majority interest in Hanxin, Chengong's parent company.
• The independent and disinterested members of Amphastar's Audit Committee evaluated and approved the agreement.

Sentiment

Score: 7

Explanation: The agreement represents a positive strategic expansion into a significant market with a long-term commitment and structured revenue mechanisms. However, the related-party nature and undeterminable total revenue introduce some uncertainty, preventing a higher score.

Positives

• Expansion of BAQSIMI distribution into the significant Greater China market.
• Exclusive distribution rights granted to Chengong, potentially streamlining market entry and penetration.
• Chengong is responsible for regulatory approvals and post-marketing clinical trials, reducing Amphastar's direct burden in these areas for the region.
• Minimum purchase amounts for Chengong provide a baseline revenue commitment for Amphastar.
• Profit-sharing mechanism allows Amphastar to benefit from higher per-unit net revenues achieved by Chengong.
• Long-term agreement (10 years) provides stability and a sustained presence in the new market.

Negatives

• Total revenue from the agreement is not determinable at this time, introducing uncertainty regarding its financial impact.
• The agreement is a related party transaction, which, despite audit committee approval, can raise questions about potential conflicts of interest or terms not being purely at arm's length.
• Reliance on Chengong for regulatory approvals and post-marketing trials means Amphastar's success in the region is dependent on Chengong's performance in these critical areas.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions.
• Changes in laws and regulations in the Greater China region could impact the agreement's performance.
• Disruptions in supply chains could affect the availability and distribution of BAQSIMI.
• Chengong's ability to obtain regulatory approvals and perform post-marketing clinical trials effectively in the Region.
• The inherent risks associated with related party transactions, even with independent committee approval.
• Uncertainty regarding the per-unit net revenues, making total revenue from the agreement undeterminable.

Future Outlook

The agreement aims to expand the distribution of BAQSIMI in the Greater China region over a ten-year term. While the total revenue is currently undeterminable, the structure includes minimum purchase amounts and profit sharing, indicating an expectation of sustained sales and potential for increased earnings. The company acknowledges standard forward-looking statement risks, including regulatory changes and supply chain disruptions.

Industry Context

This agreement represents a strategic move by Amphastar to tap into the growing pharmaceutical market in Greater China, a common expansion strategy for pharmaceutical companies seeking new revenue streams and broader market reach for their products. BAQSIMI, as a nasal powder product, likely targets a specific medical need, and securing an exclusive distributor like Chengong, which is responsible for local regulatory hurdles, is a typical approach to navigate complex international markets. The related-party nature of the transaction, while approved by the audit committee, is a point of scrutiny in corporate governance within the industry.

Comparison to Industry Standards

• The 10-year exclusive distribution agreement is a standard duration for pharmaceutical product launches in new, complex markets, providing sufficient time for market penetration and return on investment.
• Placing responsibility for local regulatory approvals and post-marketing clinical trials on the distributor (Chengong) is a common practice, especially when partnering with a local entity that possesses specific regional expertise and relationships, similar to how many Western pharmaceutical companies enter Asian markets.
• The inclusion of minimum purchase amounts and profit-sharing mechanisms aligns with typical industry distribution agreements, balancing guaranteed revenue for the manufacturer with incentives for the distributor to maximize sales and profitability.
• The related-party nature of the transaction, involving key executives, while not uncommon in closely-held or founder-led companies, typically warrants robust independent board oversight, as demonstrated by the Audit Committee's evaluation and approval, which is a standard governance practice to mitigate potential conflicts of interest.

Corporate Governance

Related Party Transactions

• The Distribution Agreement between Amphastar and Chengong is a related party transaction.
• Amphastar's CEO, President, and Director, Dr. Jack Zhang, and Chairman, COO, and Director, Dr. Mary Luo, along with certain family members, beneficially own a majority of the equity interest in Nanjing Hanxin Pharmaceutical Technology Co., Ltd., the parent company of Chengong.
• The transaction was evaluated and approved by the independent and disinterested members of Amphastar's Audit Committee.
• This related party interest was previously disclosed in the Definitive Proxy Statement for the Company's 2025 Annual Meeting of Stockholders, filed on April 14, 2025.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market expansion for BAQSIMI, but also introduces risks associated with international market entry and related-party transactions. The undeterminable total revenue adds uncertainty to future financial projections.
• Employees: No direct impact on employment mentioned, but successful market expansion could lead to future growth opportunities.
• Customers (in Greater China): Will gain access to BAQSIMI, a nasal powder product, through Chengong's distribution network.
• Regulatory Authorities (in Greater China): Chengong will be engaging with these authorities for product approvals and post-marketing requirements.

Next Steps

• Chengong will proceed with obtaining regulatory approvals for BAQSIMI in the Greater China region.
• Chengong will perform required post-marketing clinical trials for BAQSIMI in the Region.
• Amphastar will file the complete Distribution Agreement as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.
• Parties may commence negotiations on an extension of the Agreement six months prior to its expiration in October 2035.

Key Dates

Recommendation

The agreement to expand BAQSIMI into the Greater China market is a positive strategic move, offering significant long-term growth potential. The structure with minimum purchase amounts and profit sharing provides a solid framework. However, the related-party nature of the transaction, despite audit committee approval, warrants careful monitoring for potential conflicts of interest. Furthermore, the total revenue from the agreement is currently undeterminable, introducing uncertainty regarding its immediate financial impact. Given the long-term nature of the agreement and the initial uncertainties, a "hold" recommendation is appropriate, allowing investors to observe the execution and initial financial contributions before making a more definitive investment decision.

Keywords

Amphastar Pharmaceuticals, BAQSIMI, Distribution Agreement, Greater China, Nanjing Chengong Pharmaceutical, Related Party Transaction, Pharmaceuticals, Drug Distribution, SEC Filing, Form 8-K, International Expansion